Bayer HealthCare

Type: Company

Name: Bayer HealthCare

First reported May 17 2013 - Updated 11 hours ago - 3 reports

Xofigo Approval Keeps the Ball Rolling For Bayer Oncology

US-based Bayer Healthcare Pharmaceuticals, as its executives were quick to point out, has now received three new approvals for cancer indications in the last eight months.Bayer and Algeta's Xofigo employs a radioactive isotope to target bone metastas ... [Published Pharmaceutical Executive - 17 hours ago]

Entities: Bayer AG, bone metastases, Oncology, Stivarga

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Bayer buys herbal drugmaker Steigerwald

Bayer has boosted its consumer care business by acquiring fellow Germany-based company Steigerwald Arzneimittelwerk, which specialises in pharmacy-only herbal medicines.Privately-owned Steigerwald’s portfolio includes Iberogast for functional gastrointestinal ... [Published Pharma Times - May 17 2013]

Entities: Bayer AG, gastrointestinal, Kemal Malik, Marijn Dekkers, Pulmonary Arterial Hypertension

First reported May 17 2013 - Updated May 17 2013 - 1 reports

BAYER AG: Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan

-Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) for regulatory approval in Japan. CTEPH is a progressive and life-threatening disease in which it is believed ... [Published 4 Traders - May 17 2013]

Entities: Pulmonary Hypertension, Bayer AG, Bayer HealthCare, Pulmonary Arterial Hypertension, Patient

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Regeneron Q1 net income increases

Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, has reported that net income for the first quarter ended March 31, 2013 was $98.87 million, or $0.90 per diluted share, compared to $11.65 million, or $0.11 per diluted share, for ... [Published Individual.com - May 17 2013]

Entities: Regeneron, Eylea, Regeneron Pharmaceuticals Inc, Bayer HealthCare

First reported May 16 2013 - Updated May 16 2013 - 1 reports

University of California

Bayer AG Goes on a Startup Hunt

Bayer HealthCare has a matchmaker in QB3. Now it's formalizing that arrangement. The global drug giant announced Wednesday that it signed a three-year deal with the University of California institute and seed-stage funding firm Mission Bay Capital LLC ... [Published BioSpace - May 16 2013]

Entities: Bayer AG, Startup, University of California, S Science Co Ltd

First reported May 15 2013 - Updated May 16 2013 - 3 reports

Bayer AG

Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection

– Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) approved Xofigo® (radium 223 dichloride) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral ... [Published Bayer Schering Pharma - May 15 2013]

Entities: Radium, bone metastases, Bayer AG

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Global Molecular Diagnostics Market 2012-2016

TechNavio's analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. ... [Published MarketResearch.com - May 16 2013]

Entities: Molecular Diagnostics, Market, Celera Diagnostics, CELLESTIS LIMITED

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) ... [Published News from Kidney Cancer Association - May 16 2013]

Entities: Oncology, Bayer AG, Portfolio

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Double Helix launches global market research team for APAC

SINGAPORE - Due to continued demand for high quality strategic market insight from clients, global market research consultancy Double Helix announces the launch of a global market research team for APAC, based in its Singapore offices.The new team will ... [Published Campaign Asia-Pacific - May 16 2013]

Entities: Double Helix, IMS Health Inc, Primary Market, Singapore

First reported May 15 2013 - Updated May 16 2013 - 5 reports

Bayer to Present New Data Across Oncology Portfolio at ASCO 2013

/- Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product ... [Published Bio-Medicine - May 15 2013]

Entities: Oncology, Bayer AG, Portfolio

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Tokai Pharma Raises $35.5M Series E Round for Prostate Cancer Clinical Studies

(c) 2013 Dow Jones & Company, Inc.Venture investors are fueling Tokai Pharmaceuticals Inc . with $35.5 million in Series E financing as the company strives to add to a growing list of new treatment options for prostate cancer.On Wednesday, the Food and ... [Published Dow Jones Financial Information Services - May 16 2013]

Entities: Tokai Pharmaceuticals Inc, Prostate Cancer, Xtandi, Medivation Inc

First reported May 14 2013 - Updated May 14 2013 - 1 reports

MARQUIS (Ponazuril) Paste [Bayer HealthCare, LLC]

Updated Date: May 8, 2013 EST ... [Published DailyMed Drug Label Updates for the last seven ... - May 14 2013]

Entities: Ponazuril, Bayer HealthCare

Quotes

...-threatening," said Oliver Sartor, MD, North American Principal Investigator for the pivotal trial and medical director of the Tulane Cancer Center. "Xofigo has demonstrated an anti-tumour effect on bone metastases and an overall survival effect in prostate cancer, making it an important addition to the treatment of CRPC patients."

US FDA approval for cancer treatment Xofigo [Published Hospital Pharmacy Europe - 22 hours ago]

"While Wright Medical never issued a recall of its Profemur Z titanium hip implant, far too many patients implanted with the device prior to 2009 have suffered complete failure of the device, requiring often painful revision surgery" While Wright Medical never issued a recall of its Profemur Z titanium hip implant, far too many patients implanted with the device prior to 2009 have...

Wright Medical Hip Lawsuit Update: New Video Informs Patients Why Profemur Z Hip Implant Is Alleg ... [Published Business Wire - May 17 2013]

...According to Bayer "Radium 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases. The high linear energy transfer of alpha emitters may cause double-strand DNA breaks in adjacent cells, resulting in an anti-tumor effect on bone metastases. The alpha particle range from radium 223 is less than 100 micrometers, which may limit damage to the surrounding normal tissue."

Advanced Prostate Cancer Drug Xofigo Approved By FDA [Published MediLexicon - May 17 2013]

Kemal Malik, head of global development at Bayer HealthCare, noted that to date, "there is no pharmacological treatment available for CTEPH" and "there is an urgent unmet medical need for patients for whom surgery is not a viable treatment option or whose disease persists or is recurrent after surgery" . Earlier this year, riociguat was submitted for inoperable CTEPH and pulmonary arterial hypertension in the USA and Europe

Bayer buys herbal drugmaker Steigerwald [Published Pharma Times - May 17 2013]

More Content

sort by: Date \| Relevance
Xofigo Approval Keeps the Ball Rolling For Baye... [Published Pharmaceutical Executive - 17 hours ago]
US FDA approval for cancer treatment Xofigo [Published Hospital Pharmacy Europe - 22 hours ago]
Wright Medical Hip Lawsuit Update: New Video In... [Published Business Wire - May 17 2013]
Bayer HealthCare AG - Product Pipeline Analysis... [Published MarketResearch.com - May 17 2013]
Third Rock Ventures adds biotech veterans to team [Published FierceBiotech - May 17 2013]
Advanced Prostate Cancer Drug Xofigo Approved B... [Published MediLexicon - May 17 2013]
Bayer buys herbal drugmaker Steigerwald [Published Pharma Times - May 17 2013]
OPTIMIZERX CORPORATION(NDA): OPTIMIZERx Corpora... [Published 4 Traders - May 17 2013]
Regeneron Q1 net income increases [Published Individual.com - May 17 2013]
BAYER AG: Bayer Submits Investigational Drug Ri... [Published 4 Traders - May 17 2013]
Bayer's Xofigo receives US FDA approval for pro... [Published PharmaBiz - May 17 2013]
Roche, QB3 unite for startups [Published Drug Discovery News - May 17 2013]
Bayer’s Xofigo wins FDA approval for treatment ... [Published Drugtopics.com - May 17 2013]
Nektar Therapeutics' President and CEO, Howard ... [Published ADVFN UK - May 16 2013]
Nektar Therapeutics' President and CEO, Howard ... [Published ADVFN India - May 16 2013]
Bayer QB3 partner on life science startups [Published BioPortfolio - May 16 2013]
Bayer AG Goes on a Startup Hunt [Published BioSpace - May 16 2013]
Bayer Prostate Cancer Drug Gains FDA Approval [Published Genetic Engineering News - May 16 2013]
Industry Leaders, Top Deals Honored at NAIOP Ne... [Published New Jersey Business Magazine - May 16 2013]
Molecular Diagnostics Market Expected to Grow a... [Published SBWire - May 16 2013]
Ricardo Gonzalez Balboa Appointed as General Ma... [Published TickerTech.com - May 16 2013]
Bayer to Present New Data Across Oncology Portf... [Published News from Kidney Cancer Association - May 16 2013]
Strategic move to strengthen Consumer Care busi... [Published Digital Journal - May 16 2013]
Upton Law Firm Providing Free Mirena Case Reviews [Published PitchEngine - May 16 2013]
Global Molecular Diagnostics Market 2012-2016 [Published MarketResearch.com - May 16 2013]
FDA approves radium-223 dichloride for bone met... [Published Ecancer Medicalscience - May 16 2013]
FDA approves radium223 dichloride for bone meta... [Published BioPortfolio - May 16 2013]
Double Helix launches global market research te... [Published Campaign Asia-Pacific - May 16 2013]
Thanks for help with great year [Published Lebanon Daily News - May 16 2013]
Bayer begins phase III trial of regorafenib in ... [Published PharmaBiz - May 16 2013]